Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237424 | 0.86 | MAOB (0.48) | MAOBMAOASLC22A12PTPN1LMNA | |
| SCHEMBL1633991 | 0.84 | NR4A2 (0.65) | NR4A2NPC1RAB9AMRGPRX4 | |
| SCHEMBL31215373 | 0.84 | NR4A2 (0.65) | NR4A2NPC1RAB9AMRGPRX4 | |
| SCHEMBL237290 | 0.84 | MAOB (0.67) | MAOBMAOASLC22A12SMN1; SMN2 | |
| SCHEMBL954314 | 0.83 | PTPN1 (0.50) | MAOBSLC22A12PTPN1LMNAMAPT | |
| SCHEMBL237393 | 0.83 | HPGD (0.50) | MAOBSLC22A12PTPN1HPGDNR4A2 | |
| SCHEMBL2184376 | 0.82 | MAOB (0.45) | MAOBMAOASLC22A12PTPN1LMNA | |
| SCHEMBL234126 | 0.82 | MAOB (0.47) | MAOBSLC22A12PTPN1LMNAMAPT | |
| SCHEMBL2088037 | 0.82 | HPGD (0.49) | MAOBSLC22A12PTPN1HPGDNR4A2 | |
| Potassium SCHEMBL2089657 | 0.82 | HPGD (0.49) | MAOBSLC22A12PTPN1HPGDNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703991-B2 | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2365746-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | Wellstat Therapeutics Corporation (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010053910-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004442-A1 | SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS | PGD, HPD, MLYCD | MAOB 684/4885MAOA 1278/4885SLC22A12 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.